 
 
 
A Phase II Biomarker Trial of Avadomide (CC -122) in Combination with 
Nivolumab in Advanced Melanoma  
 
[STUDY_ID_REMOVED]  
 
Version 3.7 
November 22, 2019  
 
 
 
 
 
A Phase II Biomarker Trial of Avadomide ( CC-122) in 
Combination with Nivolumab in Advanced 
Melanoma  
 
Protocol  Identifying  Number:   
 Principal  Investigator:    
Statistician:  
IND/IDE  Sponsor:  Moffitt Cancer Center  
Funded by: Celgene Corporation   
 
 

 
 TABLE OF CONTENTS  
  
List of Abbreviations --------------------------------------------------------------------------------------------- ----------- -- 5 
Statement of Compliance ------------------------------------------------------------------- --------------------------------  6 
Protocol Summary ------------------------------- ------------------------------------------------------------------------------  7 
Schematic of Study Desi gn ------------------------------- -------------------------------------------------------------------  8 
1 Key Roles -------------------------- ----------------------------------------------------------------------------------------- ----- 9 
2 Introduction:  Background Information and Scientific Rationale ------------------------------- ------------  9 
     2.1 Background Information ------------------------------- ------------------------------------------------------------  9 
     2.2 Rationale ------------------------------- ----------------------------------------------------------------------------------  10 
     2.3 CC -122: Pre -Clinical and Clinical Studies ------------------------------- --------------------------------------  11 
     2.4 Rationale for CC -122 Plus Nivolumab in Melanoma ------------------------------- ----------------------  18 
3 Objectives and Purpose ------------------------------ ------------------------------------------- --------------------------  22 
4 Study Design and Endpoints ------------------------------ ---------------------------------------------------------------  22 
     4.1 Description of the Study Design ------------------------------ --------------------------- ------------------------  22 
     4.2 Study Endpoints ------------------------------ -------------------------------------------------------------------------  22 
5 Study Enrollment and Withdrawal ------------------------------ ------------------------------------------------------  23 
     5.1 Participant Inclusion Criteria ------------------------ -------------------------------------------------------------  23 
     5.2 Participant Exclusion Criteria ------------------------ -------------------------------------------------------------  23 
     5.3 Strategies for Recruitment and Retention ------------------------ -------------------------------------------  24 
     5.4 Participant Withdrawal or Termination ------------------------ ----------------------------------------------  25 
            5.4.1 Reasons for Withdrawal or Termination ------------------------ -------------------------------------  25 
     5.5 Permanent Termination or Suspension of Study ------------------------ ----------------------------------  25 
6 Study Agent ------------------------ --------------------------------------------------------------------------------------------  26 
     6.1 Study Agent(s) and Control Description ------------------------ ----------------------------------------------  26 
            6.1.1 Dosing and Administration ------------------------ --------------------------------------------------------  26 
            6.1.2 Duration of Therapy ------------------------ -----------------------------------------------------------------  26 
            6.1.3 Dose Modifications ------------------------ ------------------------------------------------------------------  27 
     6.2 Study Agent Accountability Procedures ------------------------ ----------------------------------------------  34 
7 Study Procedures and Schedule ------------------------ ----------------------------------------------------------------  34 
     7.1 Study Procedures/Evaluations ------------------------ -----------------------------------------------------------  34 
     7.2 Schedule of Events Table ------------------------ -------------------------------------------------------------------  33 
     7.3 Concomitant Medications, Treatments, and Procedures ------------------------ ----------------------  38 
     7.4 Justification for Sensitive Procedures ------------------------ -------------------------------------------------  38 
     7.5 Precautionary Medications, Treatments, and Procedures ------------------------ --------------------  38 
     7.6 Prohibite d Medications, Treatments, and Procedures ------------------------ --------------------------  39 
     7.7 Prophylactic Medications, Treatments, and Procedures ------------------------ -----------------------  39 
8 Assessment of Safety ------------------------ -------------------------------------------------------------------------------  39 
     8.1 Specification of Safety Parameters ------------------------ -----------------------------------------------------  39 
            8.1.1 Definition of Adverse Events (AE) ------------------------ ----------------------------------------------  39 
            8.1.2 Definition of Serious Adverse Events (SAE) ------------------------ ---------------------------------  39 
            8.1.3 Definition of Unanticipated Problems ------------------------ ----------------------------------------  40 
     8.2 Classification of an Adverse Event ------------------------ ------------------------------------------------------  34 
            8.2.1 Severity of Event ------------------------ ----------------------------------------------------------------------  40 
            8.2.2 Relationship to Study Agent ---------------- -------- ------------------------------------------------------  40 
            8.2.3 Expectedness ------------------------ ---------------------------------------------------------------------------  41 
     8.3 Time Period and Frequency for Event Assessment and Follow -Up ------------------------ ---------  41 
     8.4 Reporting Procedures ------------------------ -------------- ---------------------------------------------------------  42 
 
 TABLE OF CONTENTS     
  
            8.4.1 Adverse Event Reporting ------------------------ ----------------------------------------------------------  42 
            8.4.2 Serious Adverse Event Reporting --------------------------------------------------------- --------------  42 
            8.4.3 Unanticipated Problem Reporting ------------------------ ---------------------------------------------  42 
            8.4.4 Events of Special Interest ------------------------ ----------------------------------------------------------  43 
            8.4.5 Reporting of Pregnancy ------------------------ ------------------------------------------------------------  43 
  9 Clinical Monitoring ---------------------- -------------------------------------------------------------------------------- -- 44 
10 Statistical Consideration ------------------------ -------------------------------------------------------------------------  44 
     10.1 Statistical and Analytical Plans ------------------------ ---------------------------------------------------------  44 
     10.2 Analysis of the Secondary Endpoints (S) ------------------------ --------------------------------------------  44 
     10.3 Efficacy Analysis ------------------------ ------------------- ----------------------------------------------------------  45 
     10.4 Planned Interim Analyses ------------------------ ----------------------------------------------------------------  46 
            10.4.1 Exploratory Analyses ------------------------ --------------------------------------------------------------  46 
     10.5 Sample Size ------------------------ ------------------------------------------------------------------------------------  48 
  
11 Source Documents and Access to Source Data/Documents ------------------------ -----------------------  48 
12 Quality Assurance and Quality Control ------------------------ ----------------------------------------------------  48 
13 Ethics/Protection of Hu man Subjects ------------------------ ------------------------------------------------------  49 
     13.1 Ethical Standard ------------------------ -----------------------------------------------------------------------------  49 
     13.2 Institutional Review Board ------------------------ --------------------------------------------------------------  49 
     13.3 Informed Consent Process ----------- ------------- ---------------------------------------------------------------  49 
            13.3.1 Consent/Assent and Other Informational Documents Provided to Participants ---- 49 
            13.3.2 Consent Procedures and Documentation ------------------------ ---------------------------------  49 
     13.4 Participant and Data Confi dentiality ------------------------ -------------------------------------------------  50 
            13.4.1 Research Use of Stored Human Samples, Specimens or Data ------------------------ ----- 50 
     13.5 Future Use of Stored Specimens ----------------- ------- ------------------------------------------------------  50 
14 Data Handling and Record Keeping ------------------------ ---------------------------------------------------------  51 
     14.1 Data Collection and Management Responsibilities ------------------------ -----------------------------  51 
     14.2 Study Records Retention ------------------------ -----------------------------------------------------------------  52 
     14.3 Pr otocol Deviations ------------------------ ------------------------------------------------------------------------  52 
     14.4 Publication and Data Sharing Policy ------------------------ --------------------------------------------------  53 
15 Study Adm inistration ------------------------ -----------------------------------------------------------------------------  53 
     15.1 Study Leadership ------------------------ ----------------------------------------------------------------------------  53 
16 Con flict of Interest Policy ------------------------ -----------------------------------------------------------------------  54 
17 Literature References ------------------------ ----------------------------------------------------------------------------  55 
Appendix  A 58 
Appendix B  59 
Appendix C  60 
Appendix D  61 
LIST  OF ABBREVIATIONS  
5  
  
AE Adverse  Event  
ANCOVA  Analysis  of Covariance  
CFR Code  of Federal  Regulations  
CIOMS  Council  for International  Organizations  of Medical  Science  
CLIA  Clinical  Laboratory  Improvement  Amendments  
CMP  Clinical  Monitoring  Plan  
CMS  Centers  for Medicare  and Medicaid  Services  
CRF Case  Report  Form  
CRO  Contract  Research  Organization  
DCC Data  Coordinating  Center  
DHHS  Department  of Health  and Human  Services  
DSMB  Data  Safety  Monitoring  Board  
eCRF  Electronic  Case  Report  Forms  
FDA Food  and Drug  Administration  
FDAAA  Food  and Drug  Administration  Amendments  Act of 2007  
FFR Federal  Financial  Report  
GCP Good  Clinical  Practice  
GLP Good  Laboratory  Practices  
GMP  Good  Manufacturing  Practices  
GWAS  Genome -Wide  Association  Studies  
HIPAA  Health  Insurance  Portability  and Accountability  Act 
IB Investigator’s  Brochure  
ICH International  Conference  on Harmonisation  
ICH E6 International  Conference  on Harmonisation  Guidance  for Industry,  Good  Clinical  Practice:  
Consolidated  Guidance  
ICMJE  International  Committee  of Medical  Journal  Editors  
IDE Investigational  Device  Exemption  
IND Investigational  New  Drug  Application  
IRB Investigational  Review  Board  
ISO International  Organization  for Standardization  
LSMEANS  Least  Squares  Means  
MedDRA  Medical  Dictionary  for Regulatory  Activities  
MOP  Manual  of Procedures  
MSDS  Material  Safety  Data  Sheet  
NIH National  Institutes  of Health  
NIH IC NIH Institute  & Center  
OHRP  Office  for Human  Research  Protections  
PI Principal  Investigator  
QA Quality  Assurance  
QC Quality  Control  
SAE Serious  Adverse  Event  
SAP Statistical  Analysis  Plan  
SMC  Safety  Monitoring  Committee  
SOC System  Organ  Class  
SOP Standard  Operating  Procedure  
UP Unanticipated  Problem  
US United  States  
6 STATEMENT  OF COMPLIANCE   
  
The trial will be conducted  in accordance  with the ICH E6, the Code  of Federal  Regulations  on the 
Protection  of Human Subjects  (45 CFR Part 46), and the <NIH IC> Terms  of Award. The Principal 
Investigator  will assure  that no deviation from, or changes  to the protocol  will take  place without  prior  
agreement from  the sponsor  and documented  approval  from  the Institutional  Review  Board , except  
where  necessary  to eliminate  an immediate  hazard(s)  to the trial participants.  All personnel  involved  in 
the conduct  of this study  have  completed  Human Subjects  Protection  Training.  
 
I agree  to ensure  that all  staff  members  involved  in the conduct  of this study  are informed  of their  
obligation to meet  the above  commitments.  
 
 
Principal  Investigator:      
Print/Type  Name  
 
 
Signed:      Date:   

PROTOCOL  SUMMARY  
7 Avadomide plus Nivolumab  
November 22, 2019   
  
  A Phase II Biomarker Trial of CC -122 in Combination with Nivolumab in Advanced Melanoma  
 
 Précis:  
Preliminary pre -clinical data suggest that the novel immunomodulatory agent CC -122 can restore metabolic 
function of T -cells and wi ll increase immunosurveillance in melanoma. The synergy of the combination of 
CC-122 and the anti -PD1 agent nivolumab will enhance reversal of T -cell exhaustion and improve anti- tumor 
immu nity in patients with advanced melanoma.  Our goal is to link pharmacodynamic markers to immune 
mechanism of action and efficacy.  In addition, we seek to define sub -population s that may be enriched for 
response to CC -122 plus nivolumab in melanoma.    
 
Objectives:  
Primary : To determine the response rate to combination CC -122 plus nivolumab in both anti -PD1 naïve and 
anti-PD1 refractory advanced melanoma.  
Secondary : (1) To assess the toxicity of this combination.  (2) To determine the progression -free survival 
and overall survival with this combination. (3)  Examine blood and tissue -based biomarkers that will further 
our understanding of the complex interplay between the metabolic needs/changes in the tumor and the immune microenvironment.   
Population: Adults with advanced melanoma who are appropriate for treatment with anti- PD1 therapy or who are 
appropriate to resume anti- PD1 therapy after prior progression on anti -PD1 therapy with the goal of 
reversing resistance.   
      
Number  of Sites   
This study will be conducted at the Moffitt Cancer Center  
      Study Agent (s) and Administration : 
Oral CC -122 at 2mg daily for 5 consec utive days  every 7 days,  with intraveno us nivolumab  (240mg)  in days 
1 and 15 within a 28 -day cycle.    
 Study  Duration:  
Subjects will receive up to  52 weeks of therapy .  Decision to continue beyond this will be made based on 
response at that time. Based on planned futility analyses and enrollment across cohorts, the total number of subjects is anticipated to be  44-66.   
 Participant  Duration: 
Participants to be followed for up to 24 months following completion of study therapy.  
  
CC-122 + Nivolumab  
Version 3. 7 
21   

CC-122 + Nivolumab  
Version 3. 7 
Nov 22 , 2019  
27  
 cycle.  While regulatory approval for dosing at 480mg IV every 28 days was also recently obtained, we will 
maintain the approved biweekly dosing schedule in th is trial based on the safety data from Study CC -122-
HC-002 in hepatocellular carcinoma.  Dose administration of +/ - 2 days is permissible and will not constitute 
a deviation. There will be no dose adjustments for nivolumab.   Please refer  to the OPDIVO Pack age Insert 
(November -2018) for full prescribing information.   
 
 
 
 
In the absence of progression or intolerable toxicity, therapy will continue up to a maximum of 52 weeks (13 cycles).  For those patients who demonstrate continued improvement in radiographic response at scheduled restaging  (anticipated around week 48)  performed prior to reaching this landmark will be given the option of 
continuation of therapy.  This provision is based on the recently reported analysis of advanced melanoma 
patients who achieved a complete response to pembrolizumab on KEYNOTE -001 where the median time to 
achieve CR was 12 months (range, 3 -36).
44 For these subjects, therapy will continue for 1 cycle beyond CR 
(should they achieve this) or until 2 consecutive staging studies de monstrate a plateau in response.  For 
those patients achieving CR as best response prior to 52 weeks, therapy can be discontinued provided they 
have completed at least 26 weeks of treatment.  
 If either CC -122 or nivolumab require discontinuation due to tox icity attributed exclusively to that agent 
(e.g., neutropenia secondary to CC -122), the second drug can continue for the duration as outlined above.  
 
 
 
Dose  delay  criteria  apply  for all drug- related  adverse  events  regardless  of whether  or not the event  is 
attributed  to nivolumab , CC-122,  or both  unless it is explicitly clear that the toxicity is exclusive to one 
drug alone . All study  drugs  must  be delayed  until  treatment  can resume , unless in the judgement of the 
clinical investigator (with discussion with the PI), there is compelling evidence to continue one of the agents without the other . 
 
Causality should be assessed and provided individually for each study drug (CC -122 and nivo lumab ) for 
every AE/SAE based on currently available information.   Causality is to be reassessed and provided as 
additional information becomes available.  
 
6.1.3.1  CC-122 Dose Delay and/ or Modifications:  
 The criteria for dose reduction and/or interruption for non- hematological toxicities attributed to CC -122 
are listed in the following table.  Chronic Grade 2 toxicity attributed to CC -122 may warrant dose redu ction 
of CC -122. If necessary, the PI may reach out to the appropriate medical personnel at Celgene to discuss 
this further.  
  
Toxicity  Action  
Any Grade 4 including LFT elevation 
(exceptions include lymphopenia , 
asymptomatic amylase and lipase) • Discontinue CC -122 
Grade 3 or 4 clinical liver failure  • Discontinue CC -122 
6.1.2  DURATION  OF THERAPY  
6.1.3  DOSE MODIFICATIONS  
CC-122 + Nivolumab  
Version 3. 7 
Nov 22 , 2019  
28  
 If recurrence of Grade 3 event after  
dose-reduction • Reduce dose to the next lower dose level; if available  –
If none available , CC- 122 should be discontinued. 
If recurrence  of Grade  4 event after  
dose reduction • Discontinue CC -122 
Any non -hematological toxicity  
requiring interruption  for > 4 
weeks  • Discontinue CC -122 
Troponin -T/I > ULN  with 
associated  significant elevation in 
BNP or with  cardiac symptoms or 
significant  changes in ECG or 
LVEF1 • Hold CC -122 
• Consider cardiology evaluation  
• Follow troponin -T/I, BNP, and ECG at least every 7 days  
• If troponin -T/I returns to normal levels in < 7 days 
and there are no other significant cardiac findings, 
resume CC -122 at the next lower dose level  
• If troponin T/I level elevation persists > 7 days, or 
recurs upon re -challenge, discontinue CC -122 
Rash ≥  Grade 3  
 
  • If Grade 3 hold CC- 122 until recovery to grade ≤ 1; if AE 
resolution to Grade ≤ 1 occurs ≤ 8 days, reintroduce CC -
122 at the same dose level  
• If AE resolution to Grade ≤  2 or > 7 days, reintroduce 
CC122 on lower level, if available  
• Discontinue CC -122 for 2nd occurrence of ≥ Grade 3 
rash 
• For desquamating (blistering) Grade  3 or any Grade  4 
rash, discontinue CC -122 
• For maculopapular, aceiform, or pustular rashes lasting  
≤ 7 days  medical management is warranted including topical 
corticosteroids, anti -pruritic agents (if indicated) .  If this 
does not improve, oral steroids may be used.  It is likely 
that this intervention will be utilized given the overlap of 
this toxicity with nivolumab (see appendix D)  
Peripheral Neuropathy 
(neuropathies which begin or 
worsen  while  on study)  
≥ Grade 3  • Hold CC -122 
• When the toxicity resolves to ≤  Grade 2 or to baseline, 
restart CC -122 at the next lower dose level  
Allergic Reaction or Hypersensitivity  
≥ Grade 3  • Discontinue CC -122 
CC-122 + Nivolumab  
Version 3. 7 
Nov 22 , 2019  
29  
 Venous Thrombosis / Embolism  
(VTE)  
≥ Grade 2; anticoagulation 
indicated  • Hold CC -122 and start anticoagulation; re start CC -122 
(maintain dose level)  once therapeutic anticoagulation 
achieved  AND it is clinically appropriate to resume .2 
Pneumonitis / Interstitial Lung 
Disease3 
 • Grade 1: continue CC -122 
• Grade 2: interrupt CC -122; can resume at one dose 
level lower once < grade 1 AND steroid taper 
completed.  If recurrent Grade 2 toxicity  on re -
challenge , permanently discontinue CC -122 
• > Grade 3: permanently discontinue CC -122  
Other  Grade 34 • Hold one or both study drugs (based on 
attribution)  
• When the toxicity resolves to  < Grade 2, restart CC -
122 at  the next lower dose level  
       
 
1. For BNP, greater than 20% increase from baseline value  is considered significant. Any new ST segment 
or T wave changes, new bundle branch block, or new atrial or ventricular arrhythmia while on 
treatment with CC -122 is considered clinically significant.  A n absolute  decrease in LVEF of > 10% from 
baseline (ev en if asymptomatic) , or a  decrease of estimated LVEF to < 45% would mandate holding 
further CC -122 for up to 4 weeks.  If improved LVEF  (repeated 2 -4 weeks after holding drug)  to 
baseline value, resume CC -122 at next lower dose level, if available.  If the  decrease in LVEF is > 20%  
(absolute decrease)  from baseline or there is any evidence of symptomatic congestive heart failure, 
CC-122 will be permanently discontinued.  
2. There are no prospective data available on the need to interrupt immunomodulatory agents  like 
thalidomide, lenalidomide, CC -122 at the time of diagnosis of the VTE event.  However as these drugs 
are prothrombotic, it is reasonable to hold CC -122 till therapeutic anticoagulation is achieved.  For 
anticoagulants that do not require monitoring ( such as low molecular weight heparin), CC -122 will be 
restarted 7 days after the initial hold.  For drugs requiring moni toring (unfractionated hepar in, 
warfarin), CC -122 will be resumed once the aPTT or INR are in the recommended therapeutic range  for 
that individual agent, but no sooner than 7 days from the hold.   Prior to resuming CC -122, clinically 
significant symptoms or signs related to VTE (e.g., chest pain, dyspnea, etc.) should have resolved.  Persistence of leg/arm swelling (in case of DVT) would n ot be a contra -indication to resume therapy.       
3. As pneumonitis is an expected toxicity with nivolumab, it may be difficult to ascert ain the causality to 
one specific drug in this combination.  The management algorithm to be followed based on the grade of toxicity is outlined in Appendix D . 
4. Exceptions to this include lymphopenia,  asymptomatic elevation in amylase or lipase, an d isolated 
electrolyte  imbalances/abnormalities  that are not associated  with  clinical sequela e.  Isolated 
electrolyte aberrations  (e.g., sodium, potassium, magnesium, etc.)  may require appropriate exogenous 
supplementation, but repeat levels must meet criteria outlined in the table to resume therapy.  
 
   
 
C C -1 2 2 + Niv ol u m a b  
V ersi o n 3. 7 
N o v 2 2 , 2 0 1 9  
3 0   
  
 
 
 
 
 
 
G ui d eli n es f or h e m at ol o gic al t o xicit y attri b ut e d t o C C -1 2 2 : 
 
 
T oxicit y  Acti o n  
Gr a d e 2 t hr o m b ocyt o p e ni a  • N o  acti o n  
Gr a d e  3 t hr o m b ocyt o p e ni a  • H ol d u ntil r es ol uti o n t o Gr a d e  1 
• F oll o w C B C at l e ast ev ery 7 d ays  
• If r es ol uti o n t o Gr a d e  1 occ urs  ≤ 8 d ays, r ei ntr o d uc e  
C C -1 2 2  at  t h e  s a m e  d os e  l ev el  
• If A E r es ol uti o n occ urs  > 8 d ays, or ev e nt occ urs  
wit hi n t h e s a m e cycl e, r ei ntr o d uc e  C C -1 2 2  at  t h e  
l o w er d os e l ev el, if av ail a bl e  
Gr a d e  4 t hr o m b ocyt o p e ni a  • H ol d C C -1 2 2 u ntil r ec ov ery t o Gr a d e  1 
• F oll o w C B C at l e ast ev ery 7 d ays  
• R ei ntr o d uc e C C -1 2 2  at t h e  l o w er d os e l ev el, if  
av ail a bl e  
Gr a d e  3 n e utr o p e ni a  • H ol d u ntil r es ol uti o n t o Gr a d e  ≤ 1 
• F oll o w C B C at l e ast ev ery 7 d ays  
• If A E r es ol uti o n t o Gr a d e  ≤ 1 occ urs  ≤ 8 d a ys,  
r ei ntr o d uc e  C C -1 2 2  at  t h e  s a m e  d os e  l ev el  
• If A E r es ol uti o n occ urs > 8 d ays, or ev e nt occ urs  
wit hi n t h e s a m e c ycl e, r ei ntr o d uc e C C -1 2 2  at  o n e  
d os e l ev el l o w er, if av ail a bl e  
Gr a d e  4 n e utr o p e ni a  • Gr a d e 4:  H ol d C C -1 2 2 u ntil r ec ov ery t o Gr a d e  1.  
• F oll o w C B C at l e ast ev ery 7 d ays  
• R ei ntr o d uc e C C -1 2 2  at t h e  l o w er d os e l ev el, if  
av ail a bl e  
• Us e  of gr o wt h f act ors ( G -C SF,  G M -CS F)  is  p er mitt e d  
at t h e discr eti o n of t h e I nv esti g at or * 
F e bril e  n e utr o p e ni a  • H ol d f urt h er d osi n g u ntil  r ec ov ery  t o Gr a d e  ≤ 1 t h e n  
r es u m e  d osi n g at o n e  d os e  l ev el l o w er, if av ail a bl e  
• Us e  of gr o wt h f act ors ( G -C SF,  G M -CS F)  is  p er mitt e d  
at t h e discr eti o n of t h e I nv esti g at or * 
CC-122 + Nivolumab  
Version 3. 7 
Nov 22 , 2019  
31  
 Any hematological toxicity requiring  
interruption for > 3 weeks  • Discontinue CC -122 
*The use of myeloid growth factors (filgastri m, sargramostin , peg- filgastrim, or biosimilars), if considered 
should be in accordance wit h the 2015 American Society of Clinical Oncology guidelines for the use of WBC 
growth factors.45  This includes use in subjects with neutropenia and fever who are at high risk for infection -
related complications.  These high- risk features  are sepsis, age > 65 years, pneumonia, invasive fungal 
infection, other clinically documented infections, profound neutropenia (< 0.1 X 109/L) and hospitalization at 
the time of neutropenia. The growth factor should be continued until the absolute neutrophil count (ANC) 
has improved to < grade 1 (equal to or greater than 1.5 X 109/L). If resumption of CC -122 in planned at a 
lower dose (if available), growth factors should have been discontinue d at least 48 hours prior with 
reconfirmation of acceptable ANC on the day of planned resumption of treatment.  
 Additional toxicity -related precautions with CC -122: 
 CC-122 absorbs ultraviolet (UV) light between the frequencies of 290 and 700 nm and has be en shown to 
distribute to the skin and eyes in nonclinical animal studies. As a precautionary measure, it is recommended that subjects avoid prolonged exposure to UV light, wear protective clothing and sunglasses, and use UV -
blocking topical preparations while taking CC -122.   This is outlined in the informed consent document.  
   
6.1.3.2   Nivolumab Dose Del ays and/o r Modifications:  
 
Nivolumab  administration should be delayed  for the following:  
 
• Grade 2 non- skin,  drug -related adverse event, with the exception of  fatigue  
• Grade  2 drug- related creatinine, AST, ALT and/or Total Bilirubin abnormalities  
• Grade 3 skin, drug- related adverse event  
• Grade  3 drug- related laboratory abnormality,  with  the following exceptions:  
− Grade  3 lymphopenia  or asymptomatic  amylase  or lipase  does  not require  dose  delay  
− Grade  3 AST, ALT,  Total  Bilirubin  will require  dose  discontinuatio n 
• Any adverse  event,  laboratory  abnormality,  or inter -current  illness , which  in the judgment  of the 
investigator warrants delaying the dose of study medication.  
 
Participants  who  require  delay  of study  drug administration  should be re-evaluated  weekly  or more  
frequently  if clinically indicated and resume dosing when re -treatment  criteria are met.  
 
Criteria to Resume Treatment with Nivolumab:  
 
Participants  may resume  treatment  with  study  drug  when  the drug- related  AE(s)  resolve  to Grade  < 
1 or baseline value, with the following exceptions:  
• Participants  may  resume  treatment in the presence of Grade 2  fatigue  
• Participants  who  have  not experienced  a Grade  3 drug- related skin AE may resume treatment in the 
presence of Grade 2 skin toxicity  
• For participants  with  Grade  2 AST,  ALT and/or  Total  Bilirubin Abnormalities,  dosing may  resume  when 
laboratory  values  return  to baseline  and management  with  corticosteroids,  if needed, is complete.  
• Participants  with  combined  Grade  2 AST/ALT  AND  total  bilirubin  values  meeting  discontinuation  
parameters should have treatment permanently  discontinued.  
• Drug -related  pulmonary  toxicity,  diarrhea or colitis  must  have  resolved  to baseline  before  treatment  is 
resumed.  Participants  with  persistent  Grade  1 pneumonitis  after  completion  of a steroid  taper  over  at 
least  1 month  may  be eligible  for retreatment  if they are asymptomatic and with normal pulse oximetry 
CC-122 + Nivolumab  
Version 3. 7 
Nov 22 , 2019  
32  
 readings in the absence of oxygen supplementation.   
 
Participants  with  drug -related  endocrinopathies  adequately  controlled  with  only  physiologic  hormone  
replacement  may  resume  treatment  provided any symptoms attributed to this event have improved to 
baseline . If the criteria to resume  treatment are met,  the participant  should restart  treatment at the 
next  scheduled time  point  per protocol.  However,  if the treatment is withheld past  the window  period  of 
the next scheduled time  point  per protocol  to ensure  adequate  recovery  from  the adverse  event  or 
tapering  of immunosuppression,  the next scheduled time  point  will be delayed  until  dosing resumes.  
If treatment is withheld > 6 weeks  from  the last dose,  the participant  must  be permanently  
discontinued from  study  therapy . 
 
Treatment with Nivolumab should be permanently discontinued for the following:  
 
• Any Grade 2 drug -related  uveitis, eye pain  or blurred  vision  that does not respond to topical  therapy  and 
does not improve to Grade 1 severity  within  the re-treatment period  OR requires  systemic treatment 
 
• Any Grade  3 non-skin,  drug -related  adverse  event  lasting  > 7 days,  or recurs  with  the following 
exceptions  for laboratory  abnormalities,  diarrhea,  colitis,  neurologic  toxicity,  drug- related  uveitis,  
pneumonitis,  bronchospasm,  hypersensitivity  reactions,  infusion  reactions,  and endocrinopathies:  
− Grade  3 drug- related  diarrhea,  colitis,  neurologic  toxicity,  uveitis,  pneumonitis,  bronchospasm,  
hypersensitivity  reaction,  or infusion  reaction  of any duration requires  discontinuation  
− Grade  3 drug -related  endocrinopathies,  adequately  controlled  with  only  physiologic  hormone  
replacement  do not require  discontinuation.  Adrenal  insufficiency  requires  discontinuation regardless of  
control  with  hormone  replacement.  
− Grade  3 drug -related  laboratory  abnormalities  do not require  treatment discontinuation  except:  
♦ Grade  3 drug- related  thrombocytopenia  > 7 days  or associated  with  bleeding requires  
discontinuation  
♦ Any drug -related  liver function  test  (LFT)   abnormality  that  meets   the  following  criteria  
require  discontinuation:  
o Grade  3 drug -related AST, ALT or Total Bilirubin requires discontinuation 
o Concurrent AST or ALT > 3 x ULN and total  bilirubin > 2x ULN  
 
• Any Grade  4 drug- related  adverse  event  or laboratory  abnormality  (including but not limited  to 
creatinine,  AST,  ALT,  or Total  Bilirubin),  except for the following  events  which  do not require  
discontinuation:  
− Grade 4 neutropenia  < 7 days  
− Grade 4 lymphopenia or leukopenia or asymptomatic amylase or lipase  
− Isolated  Grade  4 electrolyte  imbalances/abnormalities  that are not associated  with  clinical sequelae  
and are corrected  with  supplementation/appropriate  management  within  72 hours of their onset  
− Grade  4 drug -related  endocrinopathy  adverse  events,  such as, hyper - or hypothyroidism,  or 
glucose  intolerance,  which  resolve  or are adequately  controlled  with  physiologic  hormone  
replacement  (corticosteroids,  thyroid  hormones)  or glucose -controlling  agents,  respectively,  may  
not require  discontinuation  of nivolumab.  
 
• Any event  that leads  to delay  in dosing lasting  > 6 weeks  from  the previous  dose  requires  
discontinuation,  with  the following  exceptions:  
− Dosing  delays  to allow  for prolonged steroid  tapers  to manage  drug- related  adverse  events are 
allowed.  
 
C C -1 2 2 + Niv ol u m a b  
V ersi o n 3. 7 
N o v 2 2 , 2 0 1 9  
3 3   
 T h e al g orit h ms f or m a n a g e m e nt of i m m u n e t oxicity attri b ut e d t o niv ol u m a b will f oll o w r ec o m m e n d ati o ns 
o utli n e d i n t h e O P DI V O p ack a g e i ns ert a n d l a b eli n g i nf or m ati o n ( N ov e m b er -2 0 1 8) pl us g e n er ally acc e pt e d 
g ui d eli n es f or cli nic al c ar e of I O t oxicity m a n a g e m e nt.  T h es e g ui d eli n es ar e s u m m ariz e d i n A p p e n dix D . 
 
T u m or  ass ess m e nts  s h o ul d  c o nti n u e  as  p er  pr ot oc ol  ev e n  if  d osi n g  is  d el a y e d. P eri o dic  st u dy  visits  t o  
ass ess  s af et y  a n d  l a b or at or y  st u di es  s h o ul d  als o  c o nti n u e e v er y  6 w e e ks  or  m or e  fr e q u e ntly  if  cli nic ally  
i n dic at e d d uri n g s uc h d osi n g d el ays.  
 
Tr e at m e nt of Ni v ol u m a b R el at e d I nf usi o n R e acti o ns:  
 
Si nc e  ni v ol u m a b  c o nt ai ns  o nl y  h u m a n  i m m u n o gl o b uli n  pr ot ei n  s e q u e nc es,  it  is  u nlik ely  t o  b e  
i m m u n o g e nic  a n d  i n d uc e  i nf usi o n  or  hy p ers e nsitivity  r e acti o ns.  H o w ev er,  if  s uc h   a r e acti o n  w er e  t o  
occ ur,  it  mi g ht  m a nif est  wit h  f ev er,  c hills,  ri g ors,  h e a d ac h e,  r as h,  pr uritis,  art hr al gi as,  hy p o - or  
hy p ert e nsi o n,  br o nc h os p as m,  or  ot h er  sy m pt o ms.  I nf usi o n  r e acti o ns  s h o ul d  b e  gr a d e d  acc or di n g  t o  
N ati o n al  C a nc er  I nstit ut e  C o m m o n  T er mi n ol o gy  Crit eri a  f or  A dv ers e  E v e nts  ( N CI  C T C A E   [ v ersi o n  5 . 0 ]) 
g ui d eli n es.  
 
Tr e at m e nt  r ec o m m e n d ati o ns  ar e  pr ovi d e d  b el o w  a n d  m ay  b e  m o difi e d  b as e d  o n  l oc al  tr e at m e nt  
st a n d ar ds a n d g ui d eli n es as a p pr o pri at e:  
 
F or  Gr a d e   1 s y m pt o ms:  ( Mil d  r e acti o n;  i nf usi o n  i nt err u pti o n  n ot  i n dic at e d;  i nt erv e nti o n  n ot  i n dic at e d)  
 
R e m ai n  at  b e dsi d e  a n d  m o nit or  p artici p a nt  u ntil  r ec ov ery  fr o m  sy m pt o ms.  T h e  f oll o wi n g  pr o p hyl actic  
pr e m e dic ati o ns  ar e  r ec o m m e n d e d  f or  f ut ur e  i nf usi o ns:  di p h e n hy dr a mi n e  5 0  m g  ( or  e q uiv al e nt)  a n d/ or  
p ar ac et a m ol  3 2 5  t o  1 0 0 0  m g  ( ac et a mi n o p h e n)  at  l e ast  3 0  mi n ut es  b ef or e  a d diti o n al  ni v ol u m a b  
a d mi nistr ati o ns.  
 
F or  Gr a d e  2 s y m pt o ms : ( M o d er at e  r e acti o n  r e q uir es  t h er a py  or  i nf usi o n  i nt err u pti o n  b ut  r es p o n ds  
pr o m ptly  t o  s y m pt o m atic  tr e at m e nt  [ e g,  a nti hist a mi n es,  n o n -st er oi d al  a nti - i nfl a m m at or y  dr u gs,  
n arc otics,  c ortic ost er oi ds,  br o nc h o dil at ors,  I V  fl ui ds];  pr o p hyl actic  m e dic ati o ns  i n dic at e d f or  < 2 4 h o urs).  
 
St o p  t h e  niv ol u m a b  i nf usi o n,  b e gi n  a n  I V  i nf usi o n  of  n or m al  s ali n e,  a n d  tr e at  t h e  p artici p a nt  wit h  
di p h e n hy dr a mi n e  5 0  m g  I V  ( or  e q ui v al e nt)  a n d/ or  p ar ac et a m ol  3 2 5  t o  1 0 0 0  mg  ( ac et a mi n o p h e n);  r e m ai n  
at  b e dsi d e  a n d  m o nit or  p artici p a nt  u ntil  r es ol uti o n  of  s y m pt o ms. C ortic ost er oi d  or  br o nc h o dil at or  t h er a py  
m ay  als o  b e  a d mi nist er e d  as  a p pr o pri at e.  If  t h e  i nf usi o n  is  i nt err u pt e d,  t h e n  r est art  t h e  i nf usi o n  at  
5 0 %  of  t h e  ori gi n al  i nf usi o n  r at e  w h e n  sy m pt o ms  r es olv e;  if  n o  f urt h er  c o m plic ati o ns  e ns u e  aft er  3 0  
mi n ut es,  t h e  r at e  m ay  b e  i ncr e as e d  t o  1 0 0 %  of  t h e  ori gi n al  i nf usi o n  r at e.  M o nit or  p artici p a nt  cl os ely.  If  
s y m pt o ms  r ec ur  t h e n  n o  f urt h er  niv ol u m a b  will  b e  a d mi nist er e d  at  t h at  visit.  A d mi nist er  
di p h e n hy dr a mi n e  5 0  m g  I V,  a n d  r e m ai n  at  b e dsi d e a n d  m o nit or  t h e  p artici p a nt  u ntil  r es ol uti o n  of  
s y m pt o ms. T h e  a m o u nt  of  st u dy  dr u g  i nf us e d  m ust  b e  r ec or d e d  o n  t h e  el ectr o nic  c as e r e p ort f or m ( e C R F). 
T h e f oll o wi n g  pr o p hyl actic  pr e m e dic ati o ns  ar e  r ec o m m e n d e d  f or  f ut ur e  i nf usi o ns:  di p h e n hy dr a mi n e  5 0  
m g  ( or  e q ui v al e nt)  a n d/ or  p ar ac et a m ol  3 2 5  t o  1 0 0 0  m g  ( ac et a mi n o p h e n)  s h o ul d  b e  a d mi nist er e d  at  l e ast  
3 0  mi n ut es  b ef or e  a d diti o n al  niv ol u m a b  a d mi nistr ati o ns.  If  n ec ess ary,  c ortic ost er oi ds  (r ec o m m e n d e d  
d os e:  u p  t o  2 5  m g  of  I V  hy dr oc ortis o n e  or  e q ui v al e nt)  m ay  b e  us e d.  
 
F or  Gr a d e   3 or  Gr a d e   4 s y m pt o ms:  ( S e v er e  r e acti o n,  Gr a d e  3:  pr ol o n g e d  [i e,  n ot  r a pi dly  r es p o nsiv e  
t o  sy m pt o m atic  m e dic ati o n  a n d/ or  bri ef  i nt err u pti o n  of  i nf usi o n];  r ec urr e nc e  of  sy m pt o ms  f oll o wi n g  
i niti al  i m pr ov e m e nt;  h os pit aliz ati o n  i n dic at e d  f or  ot h er  cli nic al  s e q u el a e  [ e g,  r e n al  i m p air m e nt,  
p ul m o n ary  i nfiltr at es]).  Gr a d e  4:  (lif e  t hr e at e ni n g;  pr ess or or  v e ntil at ory  s u p p ort i n dic at e d).  
 
I m m e di at el y  disc o nti n u e  i nf usi o n  of  niv ol u m a b . B e gi n  a n  I V  i nf usi o n  of  n or m al  s ali n e,  a n d  tr e at  t h e  
CC-122 + Nivolumab  
Version 3. 7 
Nov 22 , 2019  
35  
  
• Confirm  informed  consent  of potential  participant  has been obtained . 
• Review  medical  history  to determine  eligibility  based on inclusion/exclusion  criteria.  
• Review  medications  history  to determine  eligibility  based  on inclusion/exclusion criteria.  
• Perform medical  examinations  needed to  determine  eligibility  based  on inclusion/exclusion  
criteria. 
• Collect /schedule  study specific laboratory/biomarker tests and other studies that are outlined in the 
Schedule of Events . 
• Schedule biopsy of appropriate metastatic (or appropriately accessible) tumor site for biomarker 
analysis.  
 
 
Baseline Visit  (Cycle 1, Day 1 ) 
 
• Verify  inclusion/exclusion criteria  based on screening studies .  The specific eligibility is typically 
completed ahead of this visit through the Moffitt Internal Monitoring Core.  
• Obtain  serum  or urine pregnancy  test for women of child -bearing age; this could have  been 
completed and verified negative up to 72 hours prior to this visit . 
• Obtain  demographic  information,  medical  history,  and medication  history. 
• Record vital  signs  (including weight) , results  of examinations.   Recording of height is necessary only 
at scr eening or baseline visit  
• Collect  study specific laboratory/biomarker tests and other studies that are outlined in the Schedule 
of Events . This also includes standard of care assessments.  
• Administer  the study  treatment  (nivolumab plus CC -122; first dose of CC -122 to be administered in 
the Clinical Research Unit) . 
• Collect blood for biomarker analysis at 5 hours post CC -122 administration. 
 
Follow -up Visit  (Visit  2; C1 Day 15; +/ - 2 days )  
 
• Record adverse  events  as reported  by participant  or observed  by investigator.  
• Record vital  signs,  confirm medical history and perform physical examination  
• Collect  blood  for routine testing and biomarker analysis as specified . 
• Administer  nivolumab  per institutional standard.  
• Record participant’s  adherence  to treatment program.  
• Schedule/remind subject of follow -up tumor biopsy (same site as done at screening) to be done 
between days 22 and 29 of cycle 1.  
 
Follow -up Visit  (Visit  3; Cycle 2, day 1, +/ - 2 days)   
 
• Record adverse  events  as reported  by participant  or observed  by investigator.  
• Record vital  signs,  confirm medical history and perform physical examination  
• Administer  nivolum a b and provide CC -122 for home use  
• Record participant’s  adherence  to treatment program.  
 
Subsequent Visits to follow the ‘Schedule of Events’ calendar : All scheduled visits have the same window of 
+/- 2 days.  If there is a need to schedule outside of this window, this may be done at the discretion of the 
principal investigator as long as there is no perceived jeopardy to the health of the participant.  Tumor 
measurements by cross -sectional imaging will be performed every 12 weeks (+/ - 7days) unless documented 
progression or subject taken off the clinical trial.  Adverse events as reported by the subject or observed by 
the investigator will be recorded at each visit.  
CC-122 + Nivolumab  
Version 3. 7 
Nov 22 , 2019  
44  
 • A description of any changes  to the protocol  or other  corrective actions  that have  been  taken  or 
are proposed  in response  to the UP. 
 
To satisfy  the requirement  for prompt  reporting,  UPs will be reported  using the  following  timeline:  
 
• UPs that are SAEs  will be reported  to the IRB and to the DCC/study  sponsor within  <insert  
timeline  in accordance  with  policy>  of the investigator becoming aware  of the event.  
• Any other  UP will be reported  to the  IRB and  to the DCC/study  sponsor  within  <insert timeline  in 
accordance  with  policy> of the investigator becoming aware of the problem.  
• All UPs should be reported  to appropriate  institutional  officials  (as required by an institution’s  
written  reporting procedures),  the supporting agency  head (or designee),  and OHRP within  
 
 
 
 Not applicable.  
 
 
 
Although pregnancy and lactation are not considered adverse events, it is the responsibility of investigators or their designees to report any pregnancy or lactation in a subject (spontaneously reported to them), including the pregnancy of a male subject's female partner that occurs during the trial or within 120 days of completing the trial or 30 days following cessation of treatment. All subjects and female partners of male subjects who become pregnant must be followed to the completion/termination of the pregnancy. Any 
subject who becomes pregnant during the study, must be promptly withdrawn from the study and discontinue further study treatment. Pregnancy outcomes of spontaneous abortion, missed abortion, 
benign hydatidiform mole, blighted ovum, fetal death, intrauterine death, congenital anomaly, ectopic 
pregnancy, miscarriage and stillbirth must be reported as serious events (Important Medical Events). If the pregnancy continues to term, the outcome (health of infant) must also be reported.  
Such events must be reported within 24 hours of their knowledge of the event to Celgene using the Serious Adverse Event Form. Because the effect of the Celgene medicinal product on sperm is unknown, pregnancies in partners of male subjects exposed to a Celgene medicinal product will be reported by the Investigator within 24 hours of their knowledge of the event using the Serious Adverse Event Form. Depending on local legislation, this may require prior consent of the partner. Follow -up information 
regarding the outcome of the pregnancy and any postnatal sequelae in the infant will be required.  
8.4.4  EVENTS  OF SPECIAL  INTEREST  
8.4.5  REPORTING  OF PREGNANCY  
CC-122 + Nivolumab  
Version 3. 7 
Nov 22 , 2019  
46  
 the time of data analysis will be censored.  
 
 
 
Objective response rate is the primary end point in this combination trial involving an immune checkpoint 
inhibitor in combination with an immunomodulatory agent.  Response rates  per RECIST  1.1 will be 
evaluated.  RECIST  as assessed  by the investigator  will be used  as the primary  response rate efficacy  end- point and  
make  treatment  decisions. 
  Immunotherapeutic  agents  such  as nivolumab and pembrolizumab may  produce  antitumor effects  by 
potentiating  endogenous  cancer -specific  immune  responses , which  may  be functionally  anergic. The 
response  patterns  seen  with  such  an approach  may  extend  beyond the typical  time  course  of 
responses  seen  with  cytotoxic  agents,  and can manifest  a clinical response  after  an initial increase  in 
tumor  burden or even  the appearance  of new  lesions. Standard  RECIST  criteria  may  not provide  a 
complete  response  assessment  of immunotherapeutic  agents  such as nivolumab, therefore  the 
irRECIST  have  been
 developed to encompass  this.   This will also be assessed as a secondary end -point of 
efficacy.  
 Broadly,  irRECIST  includes  the concept  of treatment  beyond  progression,  if radiologic  imaging  shows  
PD, tumor  assessment  should  be repeated  ≥ 4 weeks  later  in order  to confirm  PD with  the option  of 
continuing  treatment , while awaiting  radiologic  confirmation  of progression.   If repeat  imaging shows a  
reduction in the  tumor  burden  compared  to the initial scan  demonstrating  PD, treatment  may  be 
continued  as per treatment calendar. If repeat  imaging  confirms  progressive  disease,  subjects will be 
discontinued  from  trial therapy.  In determining whether  or not the tumor  burden has increased  or 
decreased, Investigators  should consider  all target  lesions  as well as non-target  lesions. 
 In subjects  wh
o have  initial  evidence  of radiological PD, it is at the discretion  of the treating  
physician  whether  to continue  a subject on study  treatment , until  repeat  imaging  is obtained  a minimum  
of 4 weeks  later.  This decision  should be based  on the clinical  judgment  of the subject’s  overall  
clinical  condition,  including  performance  status,  clinical symptoms,  and laboratory  data.  Subjects  may  
receive treatment while  waiting  for confirmation  of PD if they are  clinically  stable  as defined  by the 
following  criteria:  
• Absence  of signs  and symptoms  indicating  disease  progression  
• No decline  in ECOG  performance  status  
• Absence  of rapid  progression  of disease  
• Absence of progressive tumo r at critical anatomical sites (e.g.,  cordcompression)  requiring  urgent  
alternative  medical intervention  
 When  feasible,  subjects  should  not be discontinued  until  progression  is confirmed.  This allowance  to 
continue  treatment  despite  initial radiologic  progression  takes  into account  the observation  that some  
subjects can have  a transient  tumor  flare  in the first few months  after  the start  of immunotherapy,  but 
with  subsequent  disease  response.  Subjects  that are deemed  clinically  unstable  are not required  to 
have  repeat  imaging  for confirmation  of progressive disease. 
 
Subjects who continue treatment beyond initial radiographic progression while awaiting confirmation 
imaging will need to be re -consented for their ongoing treatment with nivolumab an d avadomide  on the  
clinical  trial.   All other elements of the main consent including description of reasonable foreseeable risks or 
discomfort, and other alternative therapy will still apply.  
10.3  EFFICACY ANALYSIS 
CC-122 + Nivolumab  
Version 3. 7 
Nov 22 , 2019  
58  
 melanoma. Cancer 116:146 -54, 2010  
 23. Ganesan P, Piha -Paul S, Naing A, et al: Phase I clinical trial of lenalidomide in combination 
with sorafenib in patients w ith advanced cancer. Invest New Drugs 32:279 -86, 2014 
 24. Bilen MA, Fu S, Falchook GS, et al: Phase I trial of valproic acid and lenalidomide in patients 
with advanced cancer. Cancer Chemother Pharmacol 75:869 -74, 2015  
 25. Said R, Kakadiaris E, Piha- Paul  S, et al: Phase I clinical trial of lenalidomide in combination 
with bevacizumab in patients with advanced cancer. Cancer Chemother Pharmacol 77:1097 -102, 2016 
 26. Sakamuri D, Glitza IC, Betancourt Cuellar SL, et al: Phase 1 dose -escalation study of anti CTLA -
4 antibody ipilimumab and lenalidomide in patients with advanced cancers. Mol Cancer Ther, 2017  
 27. Hagner PR, Man HW, Fontanillo C, et al: CC -122, a pleiotropic pathway modifier, mimics an 
interferon response and has antitumor activity in DLBCL. Blood 126:779 -89, 2015  
 28. Jacques V, Czarnik AW, Judge TM, et al: Differentiation of antiinflammatory and 
antitumorigenic properties of stabilized enantiomers of thalidomide analogs. Proc Natl Acad Sci U S A 
112:E1471- 9, 2015  
 29. Chamberlain PP, Lopez -Girona A, Miller K, et al: Structure of the human Cereblon -DDB1-
lenalidomide complex reveals basis for responsiveness to thalidomide analogs. Nat Struct Mol Biol 21:803 -9, 
2014  
 30. Matyskiela ME, Lu G, Ito T, et al: A novel cereblon modulator recruits GSPT1 to the 
CRL4(CRBN) ubiquitin ligase. Nature 535:252 -7, 2016 
 31. Lindner S, Kronke J: The molecular mechanism of thalidomide analogs in hematologic 
malignancies. J Mol Med (Berl), 2016  
 32. Fischer ES, Bohm K, Lydeard JR, et al: Structure of the DDB1 -CRBN E 3 ubiquitin ligase in 
complex with thalidomide. Nature 512:49 -53, 2014  
 33. McCall CM, Hu J, Xiong Y: Recruiting substrates to cullin 4 -dependent ubiquitin ligases by 
DDB1. Cell Cycle 4:27- 9, 2005  
 34. Ito T, Ando H, Suzuki T, et al: Identification of a pr imary target of thalidomide teratogenicity. 
Science 327:1345- 50, 2010 
 35. Zeldis JB, Williams BA, Thomas SD, et al: S.T.E.P.S.: a comprehensive program for controlling 
and monitoring access to thalidomide. Clin Ther 21:319 -30, 1999  
 36. Lopez- Girona A, Me ndy D, Ito T, et al: Cereblon is a direct protein target for 
immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia 26:2326 -35, 
2012  
 37. Eichner R, Heider M, Fernandez- Saiz V, et al: Immunomodulatory drugs disrupt the  cereblon -
CD147- MCT1 axis to exert antitumor activity and teratogenicity. Nat Med 22:735 -43, 2016  
 38. Ito T, Handa H: Cereblon and its downstream substrates as molecular targets of 
immunomodulatory drugs. Int J Hematol 104:293 -9, 2016 
 39. LeBlanc R, Hide shima T, Catley LP, et al: Immunomodulatory drug costimulates T cells via the 
B7-CD28 pathway. Blood 103:1787 -90, 2004  
 40. O'Brien S, Thomas RM, Wertheim GB, et al: Ikaros imposes a barrier to CD8+ T cell 
differentiation by restricting autocrine IL -2 production. J Immunol 192:5118 -29, 2014 
 41. Thomas RM, Chen C, Chunder N, et al: Ikaros silences T -bet expression and interferon -gamma 
production during T helper 2 differentiation. J Biol Chem 285:2545 -53, 2010  
 42. Thomas RM, Chunder N, Chen C, et al: Ikaros  enforces the costimulatory requirement for IL2 
gene expression and is required for anergy induction in CD4+ T lymphocytes. J Immunol 179:7305 -15, 2007  
 43. Seymour L, Bogaerts J, Perrone A, et al: iRECIST: guidelines for response criteria for use in 
trials testing immunotherapeutics. Lancet Oncol 18:e143 -e152, 2017 
 44. Robert C, Ribas A, Hamid O, et al: Durable Complete Response After Discontinuation of 
Pembrolizumab in Patients With Metastatic Melanoma. Journal of Clinical Oncology 0:JCO.2017.75.6270  45. Smith TJ, Bohlke K, Lyman GH, et al: Recommendations for the Use of WBC Growth Factors: 
American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 33:3199 -212, 2015 
 46. Simon R: Optimal two -stage designs for phase II clinical trials. Control Clin Trials 10:1 -10, 
CC-122 + Nivolumab  
Version 3. 7 
Nov 22 , 2019  
59  
 1989  
 47. Jung SH, Lee T, Kim K, et al: Admissible two -stage designs for phase II cancer clinical trials. 
Stat Med 23:561 -9, 2004  
 48. Bowyer S, Prithviraj P, Lorigan P, et al: Efficacy and toxicity of treatment with the anti -CTLA -4 
antibody ipilimumab in patients with metastatic melanoma after prior anti- PD-1 therapy. Br J Cancer 
114:1084- 9, 2016  
 49. Ivanova A, Qaqish BF, Schell MJ: Continuous toxicity monitoring in phase II trials in oncology. 
Biometr ics 61:540 -5, 2005 
 50. Nishino M, Giobbie -Hurder A, Gargano M, et al: Developing a common language for tumor 
response to immunotherapy: immune -related response criteria using unidimensional measurements. Clin 
Cancer Res 19:3936 -43, 2013  
CC-122 + Nivolumab  
Version 3. 7 
Nov 22 , 2019  
61  
 Appendix B: ECOG Performance Status  
 
Grade  Description  
0 Normal  activity.   Fully active,  able   to  carry  on  all  pre-disease  
performance without restriction.  
 
1 Symptoms,  but ambulatory.  Restricted  in physically  strenuous  activity,  
but ambulatory  and able  to carry  out work  of a light  or sedentary  
nature  (e.g.,  light housework,  office work).  
 
2 In bed <50%  of the time.  Ambulatory  and capable  of all self-care,  but 
unable  to carry  out any work  activities.  Up and about  more  than  50%  of 
waking  hours.  
3 In bed >50%  of the time.  Capable  of only  limited  self-care,  confined  to 
bed or  chair  more  than  50%  of waking  hours.  
4 100%  bedridden.  Completely  disabled.  Cannot  carry  on any self- care.  
Totally  confined  to bed or chair.  
5 Dead.  
* As published  in Am. J. Clin.  Oncol.:  Oken,  M.M.,  Creech,  R.H.,  Tormey,  D.C.,  Horton,  J., Davis,  
T.E.,  McFadden,  E.T.,  Carbone,  P.P.:  Toxicity  And Response  Criteria Of The Eastern  
Cooperative  Oncology  Group.  Am J Clin Oncol  5:649- 655,  1982.  The Eastern  Cooperative  
Oncology  Group,  Robert  Comis  M.D.,  Group  Chair.  
 
  
 
   
CC-122 + Nivolumab  
Version 3. 7 
Nov 22 , 2019  
62  
 Appendix C:  iRECIST  (immune Response Evaluation Criteria in Solid Tumors)  
 
Tumor  response  will be assessed  by the RECIST 1.1 (primary) and iRECIST  (secondary) .43,50 The latter  is a 
reconciliation  of RECIST  guidelines  v1.1 with the  original immune -related Response  Criteria (irRC) . The 
latter  standard  incorporated  principles  important  for assessment  of immune -checkpoint  blocking  
immunotherapy  for cancer,  but fundamentally  differed  from  RECIST  in using 2- dimensional  tumor  
assessment.  In contrast,  iRECIST  is based  on 1-dimensional  tumor  measurement,  but it differs  from  
RECIST  guidelines  v1.1  in the following  key ways:  
 
• Under  RECIST  guidelines  v1.1,  the appearance  of new  lesions  indicates  PD. Under  iRECIST,  new  
measurable  lesions  are incorporated  in the tumor  burden,  which is used  to determine immune -related  
progressive  disease  (iPD), immune -related  partial  response  (iPR),  and immune -related  complete  
response  (iCR).  New  non-measurable  lesions preclude iCR. 
 
• Under  RECIST  guidelines  v1.1,  there is no confirmation  for PD. In addition,  responses  and iPDs must  be 
confirmed  by consecutive  scans  at least  4 weeks  apart,  assuming  no clinical  deterioration.  
 
The following  sub-section  describe s iRECIST  in detail.  
 
Tumor Burden : 
At baseline,  the tumor  burden  is the sum  of single  diameters  (short  axis for nodal  lesions,  longest  
diameter  for other  lesions)  for the target  lesions. In subsequent  scans, the diameters  of new  measurable  
lesions  are added  to the tumor  burden.  If a subject  is retreated,  then  up to 5 target  lesions  (perhaps  
different  from  the original  lesions) will be selected  and a new  baseline tumor burden will be  
established.  
 
Overall  Respons e
 at a Single Time  Point  
 
The table  below  outlines  determination  of disease  response  at a single  assessment  based  on iRECIST.  
 
iRECIST: Overall  Response  
 
Tumor  Burden  
(Baseline  and New)  Non-Target  Lesions  
(Baseline  and New)  Response  
Disappearance  of non -nodal lesions.  All 
pathologic  lymph  nodes < 10 mm (short  
axis)  Disappearance  of non-nodal lesions.  All 
pathologic  lymph  nodes < 10 mm (short  
axis)  irCRa 
≥ 30% decrease  from  baseline  Any irPRa 
≥ 20% increase  from  nadir and at least  5 
mm Any irPDa 
Neither sufficient decrease  to qualify  for 
PR nor sufficient increase  to qualify  for PD Any irSD 
Disappearance  of all non -nodal lesions.  All 
pathologic  lymph  nodes < 10 mm Any other than disappearance  of all non- 
nodal lesions  and reduction  of pathologic 
lymph nodes  < 10 mm irPRa 
 
 
 
a. Selection  as best response requires  confirmation by 2 consecutive  measur ements  at least 4 weeks  apart.  
b. If some lesions  are measured,  response  may  be inferred  from  available measurements.  For example,  growth  in evaluated  target  lesions  
may  be sufficient for irPD regardless  of status  of non-evaluated lesions.  
 
 
  Not all evaluatedb Any irNE  
 
CC-122 + Nivolumab  
Version 3. 7 
Nov 22 , 2019  
63  
 Appendix D: Immune Adverse Events Management Algorithm  
 
The following section  outlines general prin ciples for the management of immune -related adverse events .  A 
general principle is that differential diagnoses should be diligently evaluated according to  standard medical 
practice.  Non-inflammatory etiologies should be considered and appropriatel y treated.   The updated 
package insert for OPDIVO (nivolumab) will be concurrently followed to assist with clinical decision making . 
  
 
      
 
         

CC-122 + Nivolumab  
Version 3. 7 
Nov 22 , 2019  
64  
  

CC-122 + Nivolumab  
Version 3. 7 
Nov 22 , 2019  
65  
  

CC-122 + Nivolumab  
Version 3. 7 
Nov 22 , 2019  
66  
  

CC-122 + Nivolumab  
Version 3. 7 
Nov 22 , 2019  
67  
  

CC-122 + Nivolumab  
Version 3. 7 
Nov 22 , 2019  
68  
 

CC-122 + Nivolumab  
Version 3. 7 
Nov 22 , 2019  
69  
  
